<DOC>
	<DOCNO>NCT00825721</DOCNO>
	<brief_summary>This study evaluate safety efficacy three dose C-KAD Ophthalmic Solution patient loss visual function due age-related nuclear cataract</brief_summary>
	<brief_title>Dose-Ranging Study Ophthalamic Solution Patients With Loss Visual Function Due Age-Related Nuclear Cataract</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Presence nuclear sclerosis cataract BCDVA within range 20/40 20/80 Any clinical condition eye may compromise vision Presence history glaucoma Presence history diabetes Use eyedrops Use steroid</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Cataract Study</keyword>
	<keyword>Ophthalmic Study</keyword>
	<keyword>Agerelated cataract</keyword>
	<keyword>Nuclear Cataract</keyword>
	<keyword>Low grade nuclear cataract</keyword>
</DOC>